Bennett, Nadia R.; Boyne, Michael S.; Cooper, Richard S.; Royal-Thomas, Tamika Y.; Bennett, Franklyn I.; Luke, A.; Wilks, Rainford J.; Forrester, Terrence E.
Author Affiliation, Ana.
Impact of adiponectin and ghrelin on incident glucose intolerance and on weight change.
Date of Publication
Objectives: adiponectin and ghrelin are associated with adiposity and type 2 diabetes in several studies. We sought to prospectively determine the interaction of adiponectin and ghrelin in the development of adiposity and hyperglycaemia. Design: prospective observational study. Participants: 393 community-dwelling Afro-Jamaicans (mean age 47 ± 13 years; BMI 27·3 ± 6·3 kg/m2; 63% women) without glucose intolerance at baseline. Measurements: anthropometry, fasting plasma glucose, 2-h plasma glucose, insulin resistance (HOMA-IR), adiponectin and ghrelin concentrations were measured at baseline and 4·1 ± 0·9 years later. Multivariate analyses were used to explore the associations of HOMA-IR, adiponectin and ghrelin with weight change and glycaemia. Results: the mean weight change was 2·6 ± 5·5 kg. There were 114 incident cases of impaired glucose tolerance (IGT) and 35 cases of diabetes mellitus. Adiponectin was positively correlated with age and female sex (P-values < 0·01). After adjusting for age and sex, adiponectin and ghrelin were significantly correlated with weight at baseline and follow-up. However, they were not associated with weight change even after further adjustment for baseline weight. Adiponectin, but not ghrelin, was associated with 2-h glucose concentrations at follow-up even after adjusting for age, sex, HOMA-IR and BMI (P = 0·04). In the fully adjusted logistic regression model, adiponectin predicted incident IGT (OR 0·93; 95% CI: 0·87–0·99) and attenuated the effect of BMI on incident IGT. Conclusions: these longitudinal data show that adiponectin and ghrelin may not be causally involved in the development of obesity. However, adiponectin is independently associated with decreased risk of incident IGT.....